DLBCL
4
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
150%
Monoclonal Antibody
150%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
InnoCareChina - Beijing
2 programs1
1
TafasitamabPhase 3Monoclonal Antibody1 trial
Tafasitamab and LenalidomidePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
InnoCareTafasitamab
InnoCareTafasitamab and Lenalidomide
Jazz PharmaceuticalsDefibrotide
TevaTL011
Clinical Trials (4)
Total enrollment: 505 patients across 4 trials
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start: May 2024Est. completion: Dec 2029244 patients
Phase 3Recruiting
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Start: Sep 2021Est. completion: Apr 202750 patients
Phase 2Recruiting
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Start: Oct 2019Est. completion: Sep 202025 patients
Phase 2Terminated
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
Start: Sep 2010Est. completion: Sep 2013186 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 505 patients
3 companies competing in this space